Onselex has developed a nanomedicine platform engineered to transform oncology efficacy through precision drug delivery to tumors, dramatically reduced systemic toxicity, and repeated, sustained treatment.

Pancreatic cancer remains one of the most difficult cancers to treat, particularly in metastatic disease. Despite FOLFIRINOX, gemcitabine-Abraxane, and the recent approval of RASONQUE (daraxonrasib), long-term survival remains limited. Current treatments frequently cause treatment-related toxicities requiring dose reductions, treatment delays, or discontinuation, while RASONQUE also carries a significant toxicity burden.

Onselex’s ONX-1006 encapsulates paclitaxel (PTX), a widely used chemotherapy drug, in a stable polymeric nanoparticle designed to limit systemic exposure of normal cells to paclitaxel while enabling precision drug delivery to tumors.

ONX-1006 has been evaluated in more than 30 preclinical studies, generating approximately 4,000 pages of study data.

ONX-1006 established a No Observed Adverse Effect Level (NOAEL) equivalent to more than 750 mg of paclitaxel for a 60 kg adult, with no treatment-related adverse effects. This is about 3.75 times the 200 mg of paclitaxel delivered in a typical single dose of Abraxane, which is associated with substantial Grade 3 or higher toxicities. These findings support the strong preclinical tolerability of ONX-1006 and repeated, sustained treatment, with no treatment-related adverse effects observed at the NOAEL.

In pancreatic cancer xenograft models, ONX-1006 demonstrated strong antitumor efficacy, achieving 20% greater tumor reduction than Abraxane at the same total weekly paclitaxel dose. TUNEL analysis confirmed the highest level of tumor-cell death in the ONX-1006 group.

Furthermore, Onselex has established a standardized manufacturing SOP for ONX-1006 and produced 15 kg of nanoparticles, demonstrating reproducible multi-kilogram-scale manufacturing.

Based on extrapolation of its preclinical findings, Onselex has established development goals of 90% to 100% tumor elimination and a 70% one-year survival rate.

Onselex’s nanoparticle platform extends across solid tumors and neurological diseases, aiming to provide effective treatment while preserving quality of life and normal daily living.

We invite investors and strategic partners to join Onselex on our journey to transform cancer treatment and save tens of millions of lives worldwide.

We welcome the opportunity to discuss an investment in Onselex or a strategic partnership. To learn more, please contact us by email.

We look forward to welcoming you as part of Onselex’s journey.
Ernest Shin